- Duomed has a revenue forecast of €290m in 2024
- The transaction is expected to close in Q3 of 2024
- Fremman is a pan-European, mid-market investment firm
Apax Partners and Fremman Capital’s portfolio company Palex Medical has entered talks for the proposed acquisition of 100 percent of Duomed, a European medtech distributor.
